Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Innovation

Content :

Pipeline

At the end of July 2017, the R&D pipeline contained 47 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 13 are in Phase 3 or have been submitted to the regulatory authorities for approval.


All projects in clinical development

Zoom: Projects in clinical development

Expected R&D milestones

Expected R&D Milestones

Focus on immunology

Expanding our research focus through a collaboration with Regeneron, we are targeting unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, and nasal polyposis, and eosinophilic esophagitis.

Immunology is an area of growth for Sanofi and its dedicated business unit Sanofi Genzyme. It is an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we currently have two therapies on the market in the U.S. and in the European Union, and are researching and developing several new therapeutic areas, and we are studying other allergic and respiratory diseases, including asthma, and nasal polyposis, and eosinophilic esophagitis.

The first therapy, which is approved in the U.S., is for adults with inadequately controlled moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema. A second therapy, which is approved in the U.S. and Canada, is for the treatment of adults with moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.

We are also studying other allergic and respiratory diseases, including asthma, and nasal polyposis, and eosinophilic esophagitis.

Date of preparation: October 2017 - Job bag number: SAGB.SA.17.09.1197m

Updated: October 16, 2017